AHK-Cu vs GHK-Cu | What the Research Actually Shows

Q: What is the difference between AHK-Cu and GHK-Cu?

They are different tripeptides that each bind a copper ion: GHK is glycyl-L-histidyl-L-lysine, a peptide naturally present in human plasma, while AHK is L-alanyl-L-histidyl-L-lysine, a synthesized fragment. The practical difference is evidence — GHK-Cu has five decades of wound, skin, and hair research; AHK-Cu has a handful of laboratory studies focused on hair follicles.

Q: Can you mix AHK-Cu and GHK-Cu together?

Commercial serums combine them, but no published study has tested the combination for any endpoint. Synergy claims are untested; the honest starting point for combination research is that its effects are unmeasured.

AHK-Cu vs GHK-Cu comes down to one fact most comparison pages bury: GHK-Cu has five decades of published research across skin, wounds, and hair — AHK-Cu has a handful of laboratory studies, nearly all about hair follicles in a dish. They are different molecules with very different evidence, and this guide shows you exactly what each one has actually demonstrated, with every claim cited.

What You Need to Know

They are different tripeptides. GHK is glycyl-L-histidyl-L-lysine, a peptide your own plasma carries; AHK is L-alanyl-L-histidyl-L-lysine. Both bind a copper ion, which is where the “-Cu” comes from — and where the similarity mostly ends.
The evidence gap is enormous. GHK was first isolated from human serum in 1973 and has been studied ever since. The directly relevant AHK-Cu literature is essentially one 2007 ex vivo hair study plus a 1993 rat experiment on a related copper-binding peptide.
“AHK-Cu is better for hair” traces to a single in-vitro study — human hair follicles and dermal papilla cells in culture, at picomolar-to-nanomolar concentrations. No human trial of AHK-Cu has ever been published.
Neither peptide has injectable human dose-finding. Reconstitution math is the only part with exact answers — our peptide calculator handles it without inventing a dose.
GHK-Cu is the one our tested vendors stock with batch COAs; AHK-Cu mostly circulates through cosmetic serum brands and thin research-chem supply chains. Everything here concerns compounds sold strictly for non-human research use.

In This Guide

Two Different Molecules, One Copper Ion
The Evidence Gap: Five Decades vs a Handful of Studies
What the AHK-Cu Research Actually Measured
What the GHK-Cu Research Actually Shows
Which Is Better for Hair Growth?
What About Skin?
Topical, Injectable, and the Dose Problem
Can You Use AHK-Cu and GHK-Cu Together?
Where to Buy Lab-Tested Copper Peptides
Frequently Asked Questions

Two Different Molecules, One Copper Ion

Start with what the names mean, because listings blur them constantly. GHK is the tripeptide glycyl-L-histidyl-L-lysine; AHK is L-alanyl-L-histidyl-L-lysine. One amino acid differs — glycine swapped for alanine — and each peptide binds a copper(II) ion tightly enough to be sold as the complex: GHK-Cu and AHK-Cu. When a skincare label says “copper peptide” with no further detail, it almost always means GHK-Cu.

The biological difference is bigger than the chemical one. GHK is a native human molecule. It circulates in your plasma at measurable levels that fall with age — averaging around 200 ng/ml at age 20 and about 80 ng/ml by 60 (PMID 35083444). That decline is one reason researchers keep coming back to it. AHK has no comparable documented status as a circulating human peptide; it entered the literature as a synthesized copper-binding fragment studied for hair applications. Neither fact settles which does more in a follicle — but it explains why one molecule has a fifty-year paper trail and the other has a thin folder.

How listings blur the two

Expect confusion at the point of sale. Cosmetic serums often say “copper peptides,” plural, without naming either sequence; research vendors sometimes list AHK-Cu right beside GHK-Cu at similar prices, which implies an equivalence the literature doesn’t support; and hair products increasingly list both in one formula. The fix is the same one we apply everywhere: the certificate of analysis is the label that counts. A proper COA names the exact peptide and its quantity — if the document doesn’t distinguish AHK from GHK, the vendor hasn’t either.

The Evidence Gap: Five Decades vs a Handful of Studies

GHK’s paper trail starts in 1973, when Pickart and Thaler isolated a serum tripeptide that changed how liver cells behaved in culture (PMID 4349963). From there the GHK-Cu literature grew into wound-healing models across multiple species, skin-remodeling work, and controlled cosmetic studies, summarized in detailed reviews (PMID 18644225; PMID 26236730).

Now run the same exercise for AHK-Cu. Search PubMed and the directly relevant results come down to one 2007 study of human hair follicles ex vivo (PMID 17703734) and a 1993 primate-center paper in which a related copper-binding peptide, PC1031, enlarged follicles on the back skin of fuzzy rats (PMID 8326148). That’s the whole comparison, really. Every “AHK-Cu vs GHK-Cu” article you’ll find is comparing a library to a leaflet — and the honest version of this page has to say so before it says anything else.

A thin literature doesn’t mean a compound does nothing. It means nobody has measured what it does at the standard of evidence you’d want — and any page speaking about AHK-Cu with the same confidence it uses for GHK-Cu is padding the leaflet.

What the AHK-Cu Research Actually Measured

The 2007 Seoul National University study: follicles in a dish, real effects, tiny concentrations

The study behind essentially every AHK-Cu hair claim is Pyo and colleagues, published in Archives of Pharmacal Research (PMID 17703734). The team took human hair follicles kept alive ex vivo, plus cultured dermal papilla cells — the specialized fibroblasts that drive follicle growth — and exposed them to AHK-Cu at concentrations from 10⁻¹² to 10⁻⁹ molar. Three findings matter. AHK-Cu stimulated follicle elongation ex vivo. It increased dermal papilla cell proliferation in vitro. And at the top concentration it shifted apoptosis markers in the surviving direction — a higher Bcl-2/Bax ratio, less cleaved caspase-3 — though the reduction in the number of apoptotic cells itself was not statistically significant.

Note what those concentrations are: picomolar to nanomolar, in culture medium, bathing isolated tissue. That is not a dose. It cannot be converted into a serum amount, a scalp application, or an injection volume, and any product page that turns “10⁻⁹ M in a dish” into “apply X mg daily” performed that conversion with a keyboard, not an experiment.

The 1993 rat study: a cousin compound, compared to minoxidil

The older data point comes from Uno and Kurata at the Wisconsin primate center (PMID 8326148). Amid work on minoxidil and 5α-reductase inhibition, they reported that a copper-binding peptide called PC1031 enlarged vellus follicles on fuzzy-rat back skin, with an effect they described as similar to topical minoxidil. It’s a striking sentence and a limited one: rats, back skin, a related-but-distinct peptide, inside a review of many agents. When a vendor page says “AHK-Cu performed like minoxidil in studies,” this is the sentence being stretched.

What’s missing

No published human trial of AHK-Cu — not for hair regrowth, not topically against placebo, not injected. No dose-finding of any kind. No before-and-after study with controlled photography or phototrichogram counts. The in-vitro work is real and genuinely suggestive; everything built on top of it is inference.

What the GHK-Cu Research Actually Shows

The GHK-Cu file is thick enough that the honest move is summarizing its reviews and flagging their limits. Across the assembled literature (PMID 18644225; PMID 26236730), GHK-Cu accelerates wound healing in numerous animal models, stimulates synthesis of collagen and elastin, modulates metalloproteinases and their inhibitors, increases production of growth factors including VEGF and FGF-2, and increases fibroblast and keratinocyte proliferation. On hair specifically, the tissue-remodeling review reports that GHK-Cu increases hair follicle size and improved hair-transplant outcomes. On skin, it cites controlled studies in aged skin showing tightening, improved elasticity and firmness, and reduced fine lines, photodamage, and hyperpigmentation. The 2015 review goes further, proposing that GHK modulates the expression of some 4,000 genes — the authors’ framing, and a claim about gene-chip data rather than clinical endpoints.

Two caveats keep this section honest. First, much of the review literature shares an author — Loren Pickart, who discovered the peptide and ran a company built on it. The underlying studies are real; the synthesis is enthusiastic. Second, the strong evidence is overwhelmingly topical and wound-model work. Injectable GHK-Cu — the format sold as a research compound — is the least-studied route, a gap we cover in depth in our full GHK-Cu review.

Which Is Better for Hair Growth?

Here’s the sentence no comparison page wants to print: no study has ever tested AHK-Cu against GHK-Cu — not head-to-head, not in the same model, not once. “Better” is therefore a judgment about two different stacks of indirect evidence, and you should know what each stack contains.

The case for AHK-Cu is the 2007 ex vivo study: direct stimulation of human follicle elongation and dermal papilla proliferation (PMID 17703734). The case for GHK-Cu is broader but less hair-specific: follicle enlargement and transplant-outcome findings inside a much larger remodeling literature (PMID 18644225), plus its role in tested blends — it’s one quarter of KLOW, and the reason KLOW-for-hair research exists at all. Neither stack includes a placebo-controlled human hair trial of the standalone peptide. The buying side of the hair question — products, prices, and verification — is covered in our AHK-Cu for hair growth guide. If you see a page declare a winner with percentages attached, check for these tells:

A percentage with no citation. “Increases growth by 120%” appears on serum listings; it appears in no indexed study of either peptide.
Dish concentrations rewritten as doses. The AHK-Cu study used picomolar-to-nanomolar exposure ex vivo. Any mg-per-day figure derived from it was invented.
The minoxidil comparison without the rat. The “similar to minoxidil” finding involved PC1031 on fuzzy-rat back skin in 1993 — not AHK-Cu on a human scalp.
Before-and-after photos with no protocol. No controlled photographic study exists for either standalone peptide, so those images are testimonials with lighting.

It’s worth knowing what a real answer would look like, because the 1993 primate work already sketched the method: phototrichogram counts, follicular micro-morphometry, and DNA-synthesis measurements (PMID 8326148). A head-to-head trial using those endpoints on human scalps over six months would settle the question. Until someone runs it, “better for hair” is a marketing sentence wearing a lab coat — and a researcher’s working position is that AHK-Cu has the more direct follicle data and GHK-Cu has the more trustworthy supply chain and the deeper safety-adjacent literature — a gap we map fully in our AHK-Cu side effects breakdown.

What About Skin?

This one isn’t close. GHK-Cu’s controlled cosmetic studies — the aged-skin work on elasticity, firmness, wrinkles, photodamage, and hyperpigmentation — are the best-documented corner of its entire file (PMID 26236730). AHK-Cu has essentially no published skin-endpoint research; its literature went the hair direction and stopped. That evidence split is also why GHK-Cu, not AHK, appears in skin-focused research blends like GLOW. If your research interest is skin, the comparison resolves itself: one peptide has skin data, the other has a hypothesis.

Topical, Injectable, and the Dose Problem

Almost everything either peptide has demonstrated was demonstrated topically or in tissue models. The injectable vials sold by research vendors sit outside that evidence: no dose-finding study exists for injected AHK-Cu or injected GHK-Cu in humans — no tested amount, no tested frequency, no tested duration. That’s the same honest wall we document for KLOW dosing, and it doesn’t move because a label looks pharmaceutical.

What does have exact answers is the arithmetic. A 50mg GHK-Cu vial reconstituted with 2ml of bacteriostatic water holds 25mg per ml — 2.5mg per 10 units on a U-100 syringe. Our peptide calculator runs that conversion for any vial, water volume, and syringe, and deliberately stops there: it computes concentrations, not recommendations. Charts that go further — “2mg daily for 30 days” tiers for copper peptides — are constructed, and constructed recently; the studies they’d need have not been run.

Can You Use AHK-Cu and GHK-Cu Together?

Cosmetic brands sell exactly this combination — hair serums listing both peptides at gram-scale totals. So it’s worth being precise: no published study has tested AHK-Cu and GHK-Cu together, for any endpoint, by any route. There is no synergy data, no interference data, no combined-exposure safety data. The plausible-sounding rationale on product pages — “complementary mechanisms” — is an untested guess about two compounds that share a copper ion and two-thirds of a sequence. Blend research isn’t inherently unreasonable; peptide science is full of deliberate combinations, from KLOW to the BPC-157/TB-500 wolverine stack. But a researcher should log “combination effects: unmeasured” as the starting fact, because it is the only fact available.

Where to Buy Lab-Tested Copper Peptides

Supply is where this comparison turns practical. GHK-Cu is a standard catalog item with batch certificates of analysis from the vendors we test — live prices below, updated daily. AHK-Cu is not: as of this writing, none of the vendors we track stock it, and it circulates mainly through cosmetic serum brands and smaller research-chem storefronts where COA discipline is thinner. A peptide with one supporting study deserves more purity verification, not less — if a vendor can’t show a batch-matched COA identifying the peptide and its quantity, the leaflet-sized evidence base is carrying an unverified product.

Loading price comparison…

Our vendor reasoning lives in the Amino Club review and Mile High Compounds review, and the science lives in the full GHK-Cu guide — with more evidence-first guides in our guide library. Whichever way your research goes, everything on this page concerns compounds sold strictly for non-human research use.

Frequently Asked Questions

What is the difference between AHK-Cu and GHK-Cu?

They’re different tripeptides that each bind a copper ion: GHK is glycyl-L-histidyl-L-lysine, a peptide naturally present in human plasma, while AHK is L-alanyl-L-histidyl-L-lysine, a synthesized fragment. The practical difference is evidence — GHK-Cu has five decades of wound, skin, and hair research; AHK-Cu has a handful of laboratory studies focused on hair follicles.

Is AHK-Cu better than GHK-Cu for hair growth?

Unknown — no study has ever compared them. AHK-Cu stimulated human hair follicle elongation and dermal papilla cell proliferation in one 2007 ex vivo study; GHK-Cu’s larger literature reports increased follicle size and improved transplant outcomes. Neither has a placebo-controlled human hair trial as a standalone peptide.

Is there an established AHK-Cu dosage?

No. The only direct AHK-Cu study used picomolar-to-nanomolar concentrations on isolated follicles and cells — laboratory exposures, not doses. No human dose-finding exists for AHK-Cu by any route, so every dosage chart for it was constructed rather than measured.

Can you mix AHK-Cu and GHK-Cu together?

Commercial serums do combine them, but no published study has tested the combination for any endpoint. Synergy claims are untested; the honest starting point for combination research is that its effects are unmeasured.

Is AHK-Cu naturally occurring like GHK-Cu?

GHK circulates in human plasma at levels that decline with age — roughly 200 ng/ml at age 20 to 80 ng/ml by 60. AHK has no comparable documented status as a circulating human peptide; it entered the literature as a synthesized copper-binding compound.

Does GHK-Cu regrow hair?

The review literature reports increased hair follicle size and improved hair-transplant success, and a related copper peptide enlarged follicles in rats in 1993. What’s missing is a placebo-controlled human regrowth trial of GHK-Cu alone — the follicle findings are real, and they sit below the evidence standard of approved regrowth agents.

AHK-Cu vs GHK-Cu: What the Research Actually Shows